is 100% efficacious in protecting adolescents aged 12 to 15 years from COVID-19 disease.On March 31, the companies released a statement summarizing the results of their , which is already authorized in the U.S. and elsewhere for use in , in this younger age group. The results have been highly anticipated as state and local leaders—not to mention parents—are to keen send teens back to in-person school; this study suggests a path towards a return to pre-pandemic learning conditions, in which students won’t in the classroom.
The trial involved 2,260 adolescents 12 to 15 years old, randomly assigned to get two doses of theor two doses of placebo. During the study, which began earlier this year, 18 , all of them in the placebo group. The researchers found that the levels of virus-fighting antibodies generated by those receiving the vaccine were considerably higher than those receiving the placebo.
“We share the urgency to expand the use of our vaccine to additional populations and arefrom adolescents between the ages of 12 and 15,” Pfizer CEO Albert Bourla said in the statement. Based on the new data, the companies plan to ask the U.S. Food and Drug Administration (FDA) to expand emergency use authorization for the . Even more, encouraging the antibody levels exceeded those in the 16-25-year-old age group in the original adult trial of the shots. And the researchers found no significant side effects from the the teens, although they will continue to monitor them for long-term efficacy of the shot and side effects for two years.
Those data will ultimately help to enhance understanding of how. So far, seem to be affected by the virus as severely as older adults. However, protecting them from symptoms of the disease is critical, not least as an additional way to curb the . In a of adults published by the U.S. Centers for Disease Control, against symptoms of the disease but can ward off infection with the virus in the first place. The adolescent study wasn’t to confirm this in the younger population. Still, given younger people’s more responsive , it’s likely they might benefit from the same protection from infection. That would mean in a school setting because they’re less likely to get infected, to begin with.